Technology/ Title

AXL Inhibitor as Anticancer Drug

Technology Type

Biotechnology

Device/Diagnostics

Pharmaceutical

Others:_____________-

Contact Person

Name: Kuant Sung Lin

Title: Project Manager

Telephone(work): +886-02-7700-3800  ext. 5239

Mobile:

Email: ktlin2@dcb.org.tw

Link

http://

 

 

Technology Description

 

Summary of Invention:

1.      A novel AXL kinase inhibitor with patentable chemical structure distinguished from known AXL inhibitors. The regular patent has been applied.

2.      Good lead molecule significantly inhibits Gas6 ligand induced AKT phosphorylation in NSCLC and TNBC cell lines. The general in vitro potencies of our lead compound is superior to reference compound BGB324, which is currently in phase II clinical trial for treating lung cancer. In addition, this lead compound has good PK property and oral bioavailability.

 

Advantages when compared to the existing technologies:

1.   AXL inhibitor belonged to first-in-class medicine could interrupt tumor growth, blockade metastasis, overcome the drug resistance, potentiate chemotherapy, and enhance patient’s antitumor immunity. Therefore, AXL inhibitor is a novel medication for cancer treatment as well as cancer immunotherapy.

2.   The chemical structure of lead compound is different from known AXL inhibitors. The regular patent has been applied. Moreover, the in vitro potencies of lead compound is superior to reference compound BGB324. Hence, the pre-candidate compound showed the potential for further clinical development.

Intellectual Property

PCT and Taiwan patents had been applied

Key Publications

 

Business Opportunity

Cancer with high AXL expression and unmet medical need

 

 

▌技術簡介(現況)

  1. 屬新穎性AXL激酶抑制劑藥物,化學結構異於已知AXL抑制劑,目前已申請正式案專利保護。
  2. 先導藥物能有效的抑制非小細胞肺癌與三陰性乳癌細胞內的Gas6 ligand induced AKT phosphorylation且整體體外藥物活性優於標竿藥物BGB324,並且具備口服吸收性。

 

▌技術規格

具專利性之先導藥物

 

▌技術特色

  1. AXL抑制劑為市場首見新藥,具有抑制腫瘤生長、抑制腫瘤轉移、解決抗藥性、化療藥物加乘性與提升病患抗癌免疫力等功效,可以提供全新的癌症用藥選擇。
  2. 先導藥物化學結構不同於已知的AXL抑制劑,目前已申請專利保護,且藥物活性優於標竿藥物BGB324,因此深具後續的開發潛力。

 

▌應用範圍

癌症治療(具AXL高表現且無有效醫療的癌症)

 

 

▌接受技術者具備基礎建議(設備)

具備新藥開發能力

 

▌接受技術者具備基礎建議(專業)

具備新藥臨床開發經驗或承接能力者

 

▌技術分類

激酶抑制劑抗癌藥物

 

▌專利狀態

已申請專利國家: PCT與中華民國


聯絡人廖宜亭

TEL02-7700-3800 # 5297

E-mailjessieliao@dcb.org.tw

 

最後更新日期:2019.03.27